Top in endocrinology: Notable weight loss with next-gen GLP-1; erectile dysfunction risk
Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based therapies and lead to significant weight loss in adults, according to top-line results from a phase 1b/2a trial.
In a study of 125 adults with overweight or obesity, adverse events due to amycretin (Novo Nordisk) were mild or moderate and patients who were given 20 mg of amycretin for 26 weeks lost 22% of their body weight.
The results seen in the trial support the weight lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that we have previously seen with the oral formulation,” Martin Holst Lange, MD, PhD, executive vice president for development at Novo Nordisk, said in a press release.
It was the top story in endocrinology last week.
In another top story, Susan Weiner, MS, RDN, CDN, CDCES, FACES, and Brenda Jagatic, BScN, RN, CDCES, discuss the higher prevalence of erectile dysfunction in men with diabetes and how healthy lifestyle behaviors can help manage it.
Read these and more top stories in endocrinology below:
Novel obesity drug induces up to 22% weight loss with no safety concerns
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a significant weight reduction compared with placebo, according to top-line results from a phase 1b/2a trial. Read more.
Q&A: What men with diabetes should know about reducing risk for erectile dysfunction
Susan Weiner, MS, RDN, CDN, CDCES, FACES, talks with Brenda Jagatic, BScN, RN, CDCES, about the prevalence of erectile dysfunction for men with diabetes and healthy lifestyle behaviors to help lower risk. Read more.
The changing landscape of endocrinology: GLP-1s, new diabetes technology and more
The field of endocrinology saw many advancements in 2024, and more developments and innovations are anticipated in 2025. Read more.
STEP UP: High-dose semaglutide led to 21% weight loss for adults with obesity
Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than adults receiving semaglutide 2.4 mg, according to top-line results from the phase 3B STEP UP trial. Read more.
Increased screening may lead to higher thyroid cancer risk after GLP-1 initiation
Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, although increased thyroid cancer risk was observed in the first year after GLP-1 initiation, researchers reported. Read more.